Iridian Asset Management LLC CT Makes New $1.93 Million Investment in Immuneering Corporation $IMRX

Iridian Asset Management LLC CT bought a new position in Immuneering Corporation (NASDAQ:IMRX) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 275,086 shares of the company’s stock, valued at approximately $1,926,000. Iridian Asset Management LLC CT owned about 0.66% of Immuneering as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Flower City Capital bought a new stake in Immuneering during the second quarter worth approximately $108,000. Kingsview Wealth Management LLC purchased a new position in shares of Immuneering in the 2nd quarter worth approximately $47,000. Future Financial Wealth Managment LLC purchased a new position in shares of Immuneering in the 3rd quarter worth approximately $35,000. Vontobel Holding Ltd. bought a new position in shares of Immuneering during the 3rd quarter valued at approximately $150,000. Finally, Corient Private Wealth LLC purchased a new stake in Immuneering during the 2nd quarter valued at $215,000. Institutional investors own 67.65% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on IMRX. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Immuneering in a research note on Tuesday, September 30th. Needham & Company LLC lifted their price target on shares of Immuneering from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a report on Monday, December 29th. Leerink Partners initiated coverage on shares of Immuneering in a research note on Friday, October 31st. They issued an “outperform” rating and a $15.00 price objective for the company. Finally, Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Immuneering Price Performance

Shares of IMRX opened at $4.66 on Monday. The firm has a market capitalization of $300.90 million, a price-to-earnings ratio of -2.62 and a beta of 0.48. Immuneering Corporation has a 1-year low of $1.10 and a 1-year high of $10.08. The company has a 50-day moving average of $6.58 and a 200 day moving average of $5.78.

Immuneering (NASDAQ:IMRX) last issued its earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). On average, equities analysts anticipate that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.